Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) and its US partner Ollin Biosciences on Thursday announced a clinical update on IBI324 (Ollin R&D code: OLN324).

IBI324 (OLN324) is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody in Phase 1b clinical development for patients with either wet (neovascular) age-related macular degeneration (wAMD) or diabetic macular edema (DME), the leading causes of vision loss in older and working-aged people, respectively.

Ollin has completed enrolment of over 150 patients with wAMD or DME in the JADE study, a randomised, US-based, Phase 1b proof-of-concept clinical trial designed to evaluate OLN324 versus faricimab for potential areas of anatomic and durability differentiation. Topline results from the study are expected in the first quarter of 2026.

In a completed Phase 1 single and multiple dose escalation study, IBI324 (OLN324) demonstrated promising vision and anatomic improvements in DME patients along with a favourable safety profile. The antibody was discovered by Innovent and is being developed in collaboration with Ollin.